Regeneron Pharmac…
USUSDRegeneron Pharmaceuticals Inc (US:REGN) — Biotechnology: Pharmaceutical Preparations. Брой борси, на които се търгуват акциите на компанията: 2. На тази страница — цена и график, дивиденти, най-големи акционери и история на броя на акциите.
За компанията
- Уебсайт
- regeneron.com
- Сектор
- Health Care · Biotechnology: Pharmaceutical Preparations
- Централа
- Eastview, United States
- Изпълнителен директор
- Leonard S. Schleifer
- Служители
- 15 410
- Основана
- 1988
- Акции в обращение
- 101.14 млн
- Свободно търгуеми акции
- 95.85 млн
- Пазарна капитализация
- 75.65 млрд USD
- Инсайдери
- 2.09%
- Институционални инвеститори
- 93.55%
- Отрасъл (SIC)
- Pharmaceutical Preparations
- ISIN
- US75886F1075
- LEI
- 549300RCBFWIRX3HYQ56
- Коефициент на изплащане
- 8.7%
- FCF
- 3.76 млрд USD10%
- Дълг
- 1.99 млрд USDнетни парични средства
- Дивидентна история
- 1 г.
- Печалба, FCF и изплатени дивиденти — за 12-те месеца до 30.06.2026 (последният отчет на компанията).
Описание
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Дивиденти
Regeneron Pharmaceuticals Inc (REGN) изплаща дивиденти на тримесечие. През последните 12 месеца на акция са изплатени 3.7 USD (плащания: 4). Това е около 0.50% от текущата цена на акцията. Според историята на плащанията следващата екс-дивидентна дата се очаква около 17.11.2026.
| Екс-дата | Изплащане | Сума | % | Вид | Тикер |
|---|---|---|---|---|---|
| 2026-08-18 | 2026-08-31 | 0.9400 USD | 0.1/0.5 % | тримесечно | US:REGN |
| 2026-05-20 | 2026-06-04 | 0.9400 USD | 0.1/0.5 % | тримесечно | US:REGN |
| 2026-02-20 | 2026-03-05 | 0.9400 USD | 0.1/0.5 % | тримесечно | US:REGN |
| 2025-11-20 | 2025-12-05 | 0.8800 USD | 0.1/0.5 % | тримесечно | US:REGN |
| 2025-08-18 | 2025-09-03 | 0.8800 USD | 0.1/≈0.5 % | тримесечно | US:REGN |
| 2025-05-20 | 2025-06-06 | 0.8800 USD | 0.1/≈0.5 % | тримесечно | US:REGN |
| 2025-02-20 | 2025-03-20 | 0.8800 USD | 0.1/0.1 % | еднократно | US:REGN |
Новини тази седмица
Все още няма новини от сайта на компанията.
Най-големи притежатели
| Притежател | Дял | Акции | Дата на доклада |
|---|---|---|---|
| Blackrock Inc. | 9.01% | 9.11 млн | 2026-06-30 |
| Vanguard Capital Managem… | 6.56% | 6.63 млн | 2026-06-30 |
| Dodge & Cox Inc. | 4.82% | 4.87 млн | 2026-06-30 |
| State Street Corporation | 4.78% | 4.83 млн | 2026-06-30 |
| Invesco Ltd. | 3.9% | 3.94 млн | 2026-06-30 |
| JPMORGAN CHASE & CO | 3.73% | 3.77 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.23% | 3.27 млн | 2026-06-30 |
| Vanguard Portfolio Manag… | 3.14% | 3.18 млн | 2026-06-30 |
| Dodge & Cox Funds-Dodge… | 3.09% | 3.12 млн | 2026-06-30 |
| Franklin Resources, Inc. | 2.74% | 2.77 млн | 2026-06-30 |
| Geode Capital Management… | 2.6% | 2.63 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.56% | 2.59 млн | 2026-06-30 |
| Invesco QQQ Trust, Serie… | 2.19% | 2.22 млн | 2026-08-31 |
| Nuveen, LLC | 2% | 2.02 млн | 2026-06-30 |
| iShares Trust-iShares Co… | 1.32% | 1.33 млн | 2026-08-31 |
| Fidelity Concord Street… | 1.28% | 1.29 млн | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.21% | 1.22 млн | 2026-08-31 |
| PUTNAM LARGE CAP VALUE F… | 1.14% | 1.15 млн | 2026-07-31 |
| YANCOPOULOS GEORGE D (Pr… | ≈1.11% | 1.13 млн | 2025-12-31 |
| VANGUARD INDEX FUNDS-Van… | 1.1% | 1.12 млн | 2026-06-30 |
| VANGUARD SPECIALIZED FUN… | 1.06% | 1.07 млн | 2026-07-31 |
| SCHLEIFER LEONARD S (Chi… | ≈0.68% | 687 981 | 2025-12-31 |
| MURPHY ANDREW J (Officer… | ≈0.06% | 56 437 | 2025-12-05 |
| LAROSA JOSEPH J (General… | ≈0.05% | 45 595 | 2026-08-19 |
| VAN PLEW DANIEL P (Offic… | ≈0.04% | 37 730 | 2025-12-05 |
| SING GEORGE LOUIS (Direc… | ≈0.03% | 33 157 | 2026-01-02 |
| FENIMORE CHRISTOPHER R (… | ≈0.02% | 23 505 | 2026-08-18 |
| RYAN ARTHUR F. (Director… | ≈0.02% | 17 303 | 2026-07-02 |
| MCCOURT MARION E (Office… | ≈0.02% | 15 567 | 2025-12-05 |
| BROWN MICHAEL S (Directo… | ≈0.01% | 12 865 | 2026-01-02 |
